In 2022, MD simulations together with machine learning algorithms were exploited to build a personalized drug response prediction model to prognosticate the response of lung cancer patients to the EGFR TK inhibitors gefitinib and erlotinib [125]. The gene discussed is EGFR; the disease is lung carcinoma.